Annals of Surgery
Annals of Surgery
5 years ago

Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in an International Cohort

Goh, Brian K. P., Chou, Joanne F., Zheng, Jian, DeMatteo, Ronald P., Balachandran, Vinod P., Kam, Juinn Huar, Ijzermans, Jan N. M., Lee, Ser Yee, Kingham, T. Peter, Chung, Alexander Y. F., Groot Koerkamp, Bas, Lapointe, Réal, Buettner, Stefan, Turcotte, Simon, Ooi, London L. P. J., Chan, Chung Yip, Majella Doyle, Maria B., Gönen, Mithat, Vachharajani, Neeta, Jeyaraj, Prema R., Allen, Peter J., Teo, Jin Yao, Jarnagin, William R., Cheow, Peng Chung, Chow, Pierce K. H., Vandenbroucke-Menu, Franck, Chapman, William C., D’Angelica, Michael I.
imageObjective: This study aims to validate a previously reported recurrence clinical risk score (CRS). Summary of Background Data: Salvage transplantation after hepatocellular carcinoma (HCC) resection is limited to patients who recur within Milan criteria (MC). Predicting recurrence patterns may guide treatment recommendations. Methods: An international, multicenter cohort of R0 resected HCC patients were categorized by MC status at presentation. CRS was calculated by assigning 1 point each for initial disease beyond MC, multinodularity, and microvascular invasion. Recurrence incidences were estimated using competing risks methodology, and conditional recurrence probabilities were estimated using the Bayes theorem. Results: From 1992 to 2015, 1023 patients were identified, of whom 613 (60%) recurred at a median follow-up of 50 months. CRS was well validated in that all 3 factors remained independent predictors of recurrence beyond MC (hazard ratio 1.5–2.1, all P < 0.001) and accurately stratified recurrence risk beyond MC, ranging from 19% (CRS 0) to 67% (CRS 3) at 5 years. Among patients with CRS 0, no other factors were significantly associated with recurrence beyond MC. The majority recurred within 2 years. After 2 years of recurrence-free survival, the cumulative risk of recurrence beyond MC within the next 5 years for all patients was 14%. This risk was 12% for patients with initial disease within MC and 17% for patients with initial disease beyond MC. Conclusions: CRS accurately predicted HCC recurrence beyond MC in this international validation. Although the risk of recurrence beyond MC decreased over time, it never reached zero.

Publisher URL: http://journals.lww.com/annalsofsurgery/Fulltext/2017/10000/Prediction_of_Hepatocellular_Carcinoma_Recurrence.18.aspx

DOI: 10.1097/SLA.0000000000002360

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.